Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial

• Published in: Diabetes care Vol. 44; no. 3; pp. 836 - 838
• Main Authors: Blauw, Helga, Onvlee, A Joannet, Klaassen, Michel, van Bon, Arianne C, DeVries, J Hans
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01-03-2021
• Subjects: Adults; Closed loops; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Glucagon; Glucose; Insulin; Pancreas; Research design; Therapy
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc20-2106

To demonstrate the performance and safety of a bihormonal (insulin and glucagon) artificial pancreas (AP) in adults with type 1 diabetes.
In this outpatient, randomized, crossover trial, 2-week fully closed loop glucose control (AP therapy) was compared with 2-week open loop control (patient's normal insulin pump therapy with a glucose sensor if they had one).
A total of 23 patients were included in the analysis. Time in range (70-180 mg/dL [3.9-10 mmol/L]) was significantly higher during closed loop (median 86.6% of time [interquartile range 84.9-88.5]) compared with open loop (53.9% [49.7-67.2];
< 0.0001).
Compared with insulin pump therapy, the bihormonal AP provided superior glucose control, without meal or exercise announcements, and was safe in adults with type 1 diabetes.